



## Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

May 1, 2024

- Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®
- The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022)<sup>1</sup>
- Although symptoms are present in childhood, a significant portion of women with ADHD don't receive a diagnosis until they are adults<sup>2</sup>

ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals to share her personal journey with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses in adults – as well as her experience with Qelbree (viloxazine extended-release capsules), a non-stimulant medication for the treatment of ADHD.<sup>3</sup>

Busy has been vocal about her personal experience living with ADHD for years, but now she is revealing what it means to be a woman navigating ADHD and wants other women who may be struggling to know they are not alone. Boys are two times more likely than girls to be diagnosed.<sup>4</sup> While boys' symptoms often fit the stereotypical ideas of hyperactive ADHD, girls' inattentive symptoms are often overlooked. As a result, ADHD often goes undiagnosed in young girls, leading to more adult females being undiagnosed and therefore untreated – a sentiment reflective of Busy's own experience.<sup>2,5</sup>

"As women, we tend to mask or overcompensate for our ADHD symptoms and end up working harder to get things done. With the right medication, there's a sense of relief for women with ADHD – you're suddenly able to take a deep breath," says Busy. "Since I started treatment with Qelbree, I have been able to better manage my ADHD symptoms and understand what to prioritize versus what can be put on the backburner. I'm excited to collaborate with Supernus as a woman navigating ADHD and shed light on the importance of finding the right treatment by empowering others facing similar challenges."

The partnership comes just in time for Mental Health Awareness Month, an important moment to raise awareness around mental health conditions and overall wellness – including approximately 10 million adults living with ADHD in the United States.<sup>3</sup>

"Supernus seeks to encourage and lift up those living with ADHD to talk to their doctor about managing and treating their condition, especially during Mental Health Awareness Month," says Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. "We're excited to see that more women with ADHD, including Busy, are able to manage their ADHD symptoms with the help of Qelbree."

For more information about Qelbree, visit [Qelbree.com](https://www.qelbree.com). Patients should speak to a doctor about all the medications they take, and to see if Qelbree could be right for them.

### INDICATION

Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.

### IMPORTANT SAFETY INFORMATION

**Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child's moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.**

#### **You or your child should not take Qelbree if you or your child:**

Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

**Qelbree can increase blood pressure and heart rate.** Your or your child's doctor will monitor these vital signs.

**Qelbree may cause manic episodes in patients with bipolar disorder.** Tell your doctor if you or your child show any signs of mania.

**Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child.** Qelbree may cause you or your child to feel sleepy or tired.

**The most common side effects of Qelbree** in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](https://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning, for Qelbree [here](#).

<sup>1</sup>Russell, J., et al. (2023). *Number of ADHD Patients Rising, Especially Among Women*. Epic Research.

<sup>2</sup>Holthe, M. E. G., Langvik, E. (2017). *The Strives, Struggles, and Successes of Women Diagnosed with ADHD as Adults*. SAGE Journals.

<sup>3</sup>Culpepper, L., Mattingly, G. (2010). *Challenges in Identifying and Managing Attention-Deficit/Hyperactivity Disorder in Adults in the Primary Care*

*Setting: A Review of the Literature.* Primary Care Companion Journal of Clinical Psychiatry.

<sup>4</sup>Reuben C., Elgaddal N. (2024) *Attention-deficit/hyperactivity disorder in children ages 5–17 years: United States, 2020–2022.* NCHS Data Brief, no 499. Hyattsville, MD: National Center for Health Statistics.

<sup>5</sup>Quinn, P. O., Madhoo, M. (2014). *A Review of Attention Deficit/Hyperactivity Disorder in Women and Girls: Uncovering This Hidden Diagnosis.* Prim Care Companion CNS Disord.

**About Supernus Pharmaceuticals, Inc.**

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit [www.supernus.com](http://www.supernus.com).

**CONTACTS:**

Jack A. Khattar, President and CEO  
Timothy C. Dec, Senior Vice President and CFO  
Supernus Pharmaceuticals, Inc.  
Tel: (301) 838-2591

Or

**INVESTOR CONTACT:**

Peter Vozzo  
ICR Westwicke  
Office: (443) 213-0505  
Email: [Peter.Vozzo@westwicke.com](mailto:Peter.Vozzo@westwicke.com)

**MEDIA CONTACT:**

Heidi Donato  
Tel: (516) 359-1146  
Email: [Heidi.Donato@bcw-global.com](mailto:Heidi.Donato@bcw-global.com)



Source: Supernus Pharmaceuticals, Inc.